Insights
Insights From Our Experts
Articles
Case Study: Optimizing use of Field Reimbursement Managers
Navigating the complexities of insurance coverage can be a time consuming and challenging task. Field Reimbursement Managers (FRMs) were introduced as a way to help healthcare providers address issues or challenges related to securing timely access…
Case Study: Waste Reduction through Packaging Optimization
Pharmaceutical companies are being challenged to develop more effective delivery mechanisms of their therapies in order to reduce the amount of product waste. Recent changes in legislation, including the Waste Reduction Act of 2022 and adoption…
Video: New Cardiovascular Events after COVID-19 Infection
As we continue to learn more about COVID-19 and how the virus impacts the entire body, more information is coming to light regarding its impact specific to the heart and cardiovascular system. The cardiovascular complications of…
Next Generation Brand Planning: Fueling Brand Plan Efficiency Through Seamless Integration
Pharmaceutical companies are facing mounting pressures to better integrate and streamline their annual brand planning approaches to meet stakeholder needs and brand and portfolio goals. Despite being one of the most important commercial exercises in any…
Successfully Navigating Self-Commercialisation in Europe
Introduction As discussed in our previous paper, Successful Launches in Europe: Complex, But Not Complicated?,, Europe is one of the world’s largest and most important regions of focus for pharmaceutical and biotechnology manufacturers looking to treat…
Successful Launches in Europe: Complex, but Not Complicated?
Europe represents a major pharmaceutical market – it accounts for 22% of the global market, second only to the U.S. in terms of market size and has a large population of over 500 million. Understandably, pharmaceutical…
Accelerated Approval Pathways: Manufacturers Left to Grapple With Risk Versus Reward
Oncology and hematology are extremely complex, crowded and chaotic therapeutic areas. With 30% of drug approvals by the FDA occurring in the oncology and hematology space, manufacturers of these high-science brands are often faced with unprecedented…
Understanding the Inflation Reduction Act: Inflation Rebates
Posted by
Brian Abraham , Michael Kurland , Denise Woltemath , Kevin McDermott on March 9, 20233/9/23
Prescription drug manufacturers routinely implement price increases for a variety of reasons that support their business. With the passage of the Inflation Reduction Act late in 2022, Congress added a twist to these price increases. One…
The Pitfalls of Government Price Setting: Value Assessments in the U.S. vs. Germany
As the U.S. considers implementation of the drug pricing provisions of the Inflation Reduction Act (IRA), which includes price negotiation for a limited subset of drugs, it is important to understand the nuances of a government…
Filling the Missing Spaces in Your Network Meta-Analysis: The Role of Surrogate Models
Network Meta-Analysis Network meta-analysis is a statistical method that combines data from multiple randomized controlled trials to compare the relative effectiveness of different interventions (Dias et al. 2011). This method allows researchers to synthesize the results of…